Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is an aggressive malignancy and the second leading cause of cancer-related deaths worldwide. Conventional biomarkers exhibit poor performance in the surveillance, diagnosis, and prognosis of HCC. MicroRNAs (miRNAs) are a class of evolutionarily conserved small non-coding RNAs that are involved in the regulation of gene expression and protein translation, and they play critical roles in cell growth, differentiation, and the development of various types of cancers, including HCC. Recent evidence revealed the role of miRNAs as potential novel and ideal biomarkers for HCC. miRNAs are released to extracellular spaces, and they are extremely stable in bodily fluids, including serum or plasma, where they are packaged into various microparticles or associated with RNA-binding proteins. Numerous studies have demonstrated that circulating miRNAs have potential applications as minimally invasive biomarkers for HCC diagnosis and prognosis. The present review highlights current understanding of miRNA biogenesis and the origins and types of circulating miRNAs. We summarize recent progress in the use of circulating miRNAs as diagnostic and prognostic biomarkers for HCC. We also discuss the challenges and perspectives of the clinical utility of circulating miRNAs in HCC.

Key Words: Circulating microRNAs; Diagnosis; Prognosis; Hepatocellular carcinoma; Biomarkers

Core tip: MicroRNAs (miRNAs) play critical roles in cell growth, differentiation, and the development of hepatocellular carcinoma (HCC). The study of circulating miRNAs is a rapidly growing field of research, indicating the potential applications of miRNAs as minimally invasive biomarkers for HCC diagnosis, recurrence monitoring and prognosis. This review highlights current understanding of miRNA biogenesis and the origins and types of circulating miRNAs and summarizes recent progress in the study of circulating miRNAs as diagnostic and prognostic biomarkers for HCC. We also discuss the challenges and perspectives regarding the clinical utility of circulating miRNAs in HCC.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the seventh most common malignancy and the second leading cause of cancer-related deaths worldwide. Globally, there are approximately 750000 new cases and 700000 deaths of HCC reported per annum[1-3]. Two well-known risk factors for HCC are chronic viral hepatitis B (HBV) and C (HCV), which account for 80%-90% of all HCC cases worldwide. Other risks for HCC include obesity, diabetes, vitamin D deficiency, aflatoxin B1 exposure, alcoholic and non-alcoholic liver cirrhosis[4,5]. However, the underlying mechanism of HCC has not been entirely elucidated. Surgical resection and orthotopic liver transplantation are the best curative tools for the long-term survival of HCC patients. However, surgical resection is not feasible in more than 80% of HCC patients because of tumor location, tumor size or severity of the underlying liver disease. Only 5%-15% of HCC patients are potentially resectable[6,7]. The overall five-year survival rate in patients with HCC is very low, ranging from 5% to 9%. The cumulative five-year recurrence rate is approximately 70% to 80% even after curative surgical resection. Recurrence after resection generally results in a high rate of mortality[8]. Therefore, the most urgent needs are the identification of sensitive and specific markers for early diagnosis, the monitoring of recurrence and the prediction of prognosis for HCC.

Current methods for HCC diagnosis are classified into the following main categories: imaging [abdominal ultrasonography, magnetic resonance imaging (MRI), and contrast-enhanced computed tomography (CT)] and laboratory biomarker analysis [serum alpha-fetoprotein (AFP) levels][9,10]. However, the diagnostic performance of imaging technologies is unsatisfactory, particularly for the diagnosis of small lesions and early-stage HCC[11,12]. AFP is the most commonly used tumor marker for HCC diagnosis and prognosis prediction, but the false negative rate using AFP level alone is as high as 40% for patients with early-stage HCC. AFP levels remain normal in 15%-30% of all the patients, even patients with advanced HCC[6,13]. Therefore, the American Association for the Study of Liver Disease Practice Guidelines discarded AFP for surveillance and diagnosis because of its low sensitivity (39%-64%) and specificity (76%-94%)[14]. Therefore, the identification of novel and ideal biomarkers with high specificity and sensitivity for HCC diagnosis is desperately needed. Circulating microRNAs (miRNAs) have received remarkable attention because they offer great advantages and good performance as novel biomarkers for HCC diagnosis and prognosis prediction[15].

Emerging evidence demonstrated that miRNAs are an important class of non-coding RNAs as tumor oncogenes or suppressors that are involved in the HCC development[16]. miRNAs are endogenous nucleotides that are found in intra- and extracellular spaces, such as blood, urine and saliva[15,17]. Cellular miRNAs are also released, detected and quantified in the blood[18]. Circulating miRNAs exhibit several obvious advantages as potentially novel and ideal diagnostic biomarkers, including significant stability in various types of body fluids, resistance to endogenous RNase digestion, low cost, ease of analysis, and sensitive detection methods, such as real-time quantitative polymerase chain reaction (qRT-PCR)[19-21]. The above characteristics of circulating miRNAs and the limitations of currently available non-invasive methods to monitor HCC indicate that circulating miRNAs are a rapidly growing field of research that hold great promise for the development of reliable biomarkers for the diagnosis and monitoring of HCC[6,20,22].

This review highlights miRNA biogenesis and the types and origins of circulating miRNAs, summarizes recent findings of circulating miRNAs as prognostic and predictive biomarkers for HCC, and addresses challenges and perspectives for the clinical utility of circulating miRNAs in HCC.

miRNA BIOGENESIS AND FUNCTION

miRNAs are single-stranded, non-coding RNA strands of 19-25 nucleotides that regulate more than 50% of all protein-coding genes in mammals[23,24]. There are 1881 human miRNAs sequences registered in the miRBase database. The synthesis of miRNAs primarily consists of two steps, including nuclear synthesis within and outside of the nucleus[25] (Figure 1). First, RNA polymerase II transcribes miRNAs in the nucleus into primary miRNAs (pri-miRNAs) that are several hundred nucleotides in length[26,27]. Subsequently, the microprocessor complex, which consists of DiGeorge syndrome critical region gene (DGCR8) and the nuclease Drosha, cleaves the pri-miRNAs into miRNA precursors (pre-miRNAs) of approximately 60 to 70 nucleotides[3,28,29]. Exportin-5 transports the pre-miRNAs from the nucleus to the cytoplasm[25,30,31]. The pre-miRNAs are further processed in the cytoplasm by RNase Dicer to final miRNA duplexes (miRNA-miRNA^*) of 19-25 nucleotides[32,33]. Finally, the mature single-stranded miRNAs are generated and retained to form RISC (RNA-induced silencing complex), which is destined for mRNA repression/cleavage, but its passenger strand (miRNA^*) undergoes degradation[33-35]. Mature miRNAs recognize and bind to the 3′ untranslated region (UTR) of multiple mRNA targets with imperfect or perfect complementarity, which enables one specific miRNA to inhibit the translation of multiple genes[36]. Multiple miRNAs may also regulate one mRNA[17]. miRNAs participate in many key cellular processes, including proliferation, cell cycle, apoptosis, and metastasis[7,37]. The involvement of miRNAs in cancer is well established because miRNAs behave as tumor-suppressor genes or oncogenes, depending on the cellular function of their targets[38,39]. Growing evidence indicates that miRNAs may become a new tool for HCC diagnosis, prognosis, and therapy[38,40,41].

Figure 1 MicroRNAs biogenesis and function. In the nucleus, pri-miRNAs are transcribed by RNA Polymerase II (Pol II) to pre-miRNAs after processing by the microprocessor complex, which consists of Drosha and DGCR8. Pre-miRNAs are exported from the nucleus to the cytoplasm by exportin-5 and processed into the miRNA-miRNA* duplex by Dicer. The duplex is separated into two strands: one strand is selected as the mature miRNA, and the other strand is degraded. Mature miRNAs are incorporated into RISC (RNA-induced silencing complex) to produce target mRNA repression (imperfect complementarity) or mRNA cleavage (perfect complementarity). pri-miRNAs: Primary miRNAs; Pol II: RNA Polymerase II; pre-miRNAs: MiRNAs precursor; DGCR8: DiGeorge syndrome critical region gene; miRNA: MicroRNA; RISC: RNA-induced silencing complex.

ORIGINS, TYPES, AND FUNCTION OF CIRCULATING MIRNAS

The mechanisms through which circulating miRNAs originate have been established recently. Figure 2 shows that circulating miRNAs originate from the following mechanisms: (1) active secretion via membrane vesicles; (2) active secretion in protein-miRNA complexes and lipoprotein complexes (such as high-density lipoproteins); (3) active secretion via exosomes when a multivesicular body fuses with the cell membrane; and (4) passive secretion originating from cell necrosis and apoptosis[42-46]. Some research has demonstrated that circulating miRNAs exist in two different types, circulating protein-bound miRNAs or circulating microparticle miRNAs[18,43,47,48]. Circulating microparticle miRNAs are circulating miRNAs that are packaged into microparticles. Three different types of microparticles were defined by their size, mechanisms of production, and protein and lipid content[49]: (1) exosomes (40 to 100 nm in diameter; released by exocytosis from multivesicular bodies); (2) microvesicles (100 to 1000 nm in diameter; released via plasma budding); and (3) apoptotic bodies (1000 to 4000 nm in diameter; released by cells executing apoptotic process)[20,43,50,51]. Circulating protein-bound miRNAs are circulating miRNAs that are associated with specific RNA-binding proteins and lipoproteins, such as Ago2[52], which is a component of the RNA-induced silencing complex, and high-density lipoproteins (HDL)[53]. One study demonstrated that the majority of circulating miRNAs were associated with protein complexes rather than vesicles[52], but other reports indicated that circulating miRNAs were selectively sorted to microparticles or protein complexes[54-57]. Notably, both types of circulating miRNAs vary in different types of liver disease. Bala and co-workers reported that circulating miR-122 and miR-155 are predominantly associated with the exosome-rich fraction in alcoholic liver disease and inflammatory liver injury, but these miRNAs are present in the protein-rich fraction in drug-induced liver injury. Therefore, these results suggest that the shift in different types of circulating miRNAs may provide further specificity of the mechanisms of liver pathology[22].

Figure 2 Mechanisms of microRNAs secretion into blood vessels; origins and types of circulating microRNAs. miRNAs can be secreted from living cells into the extracellular environment (such as blood vessels) via the following mechanisms: (1) active secretion via exosomes; (2) active secretion via microvesicles; (3) active secretion in protein-miRNA complex (Ago2) and lipoprotein complex (such as HDL); and (4) passive secretion through apoptotic bodies. Circulating miRNAs may originate from immune cells, endothelial cells of other organs, and cancer-specific cells. In the blood, miRNAs can circulate as circulating protein-bound miRNAs or circulating microparticle miRNAs. Three types of microparticles are found in circulating blood: exosomes, microvesicles and apoptotic body. Circulating miRNAs are also present as protein-bound miRNAs. These miRNAs are primarily associated with specific RNA-bind proteins and lipoproteins, such as Ago2 and HDL. AGO: Argonaute; HDL: High-density lipoprotein; miRNAs: MicroRNAs; MVB: Multivesicular body.

A recent study identified miRNAs in many body fluids, including serum and plasma[58]. Circulating miRNAs in body fluids are packaged into microparticles or bound to proteins, which provides stability and resistance to plasma RNase digestion and enables miRNA transfer from one cell to another during diverse biological processes[59]. Circulating miRNAs exhibit paracrine effects on tumor growth[60,61]. If tumors are defined as relatively homogeneous cancer cells that are formed in an independent microenvironment, circulating miRNAs may play a novel role as regulators of intercellular communications during tumor formation[62,63]. Aside from their functional roles in tumorigenesis, circulating miRNAs represent a less invasive alternative for diagnostic testing. Easily assessable serum-based miRNAs may provide novel biomarkers of diagnostic, prognostic and predictive values for HCC, specifically in the field of hepatology.

CIRCULATING MIRNAS AS NOVEL BIOMARKERS FOR HCC DIAGNOSIS AND PROGNOSIS

The first description of the presence of circulating miRNAs in serum and their potential as cancer markers was reported by Lawrie et al[64] in 2008. This study demonstrated the overexpression of miR-155, miR-21 and miR-210 in patients with diffuse large B-cell lymphoma compared to healthy controls. Notably, high miR-21 levels were associated with the relapse-free survival of these patients[60]. Multiple studies identified circulating miRNAs as diagnostic and prognostic markers for a wide range of malignancies, which primarily used blood plasma or serum for their analyses[48].

Evidence also suggests that miRNAs are widely involved in HCC carcinogenesis, differentiation and metastasis. Aberrant miRNA expression was reported in HCC patients and cell lines. More information on aberrant miRNA expression in HCC is available in comprehensive reviews[3,40]. Therefore, circulating miRNAs should be affected during HCC development and progression. Various reports demonstrated the potential clinical application of circulating miRNAs in HCC diagnosis and prognosis.

Single circulating miRNAs as biomarkers for HCC diagnosis

The identification of a single or several individual circulating miRNAs as biomarkers for HCC diagnosis is expected. This approach has a unique advantage because it is much simpler and more straightforward compared to the detection of all circulating miRNAs. For example, miR-122 in the liver was the most abundant liver-specific miRNA, and it accounted for 70% of the total hepatic miRNAs[65]. MiR-122 plays a critical role in liver homeostasis and hepatocarcinogenesis[66]. Xu et al[67] and Qi et al[68] found elevated levels of circulating miR-122 in patients with HCC compared to healthy individuals. Qi et al[68] revealed that serum miR-122 was a potential marker for the discrimination of HCC patients from healthy controls with an AUC (the area under the receiver operating characteristic curve) of 0.869, and a cut-off value of 0.475. The sensitivity and specificity for serum miR-122 were 81.6% and 83.3%, respectively. Xu et al[67] found similar results. These results suggest that circulating miR-122, which is a liver-specific miRNA, may serve as a potential marker for HCC diagnosis. MiR-21 is also a promising biochemical biomarker for HCC diagnosis because plasma levels of miR-21 are notably higher in HCC patients than in healthy volunteers and patients with chronic hepatitis[69]. Zhang et al[6] demonstrated that serum miR-143 and miR-215 were valuable biomarkers to distinguish HCC from healthy controls with an AUC of 0.795 (sensitivity and specificity were 71% and 83%, respectively) and 0.816 (sensitivity and specificity were 80% and 91%, respectively), respectively.

However, the specificity of the detection method for a single or several individual HCC-related circulating miRNAs is relatively poor. For example, increased levels of circulating miRNA-122 are found in HCC, HBV infection[70], HCV infection[71], non-alcoholic fatty-liver disease[72], liver cirrhosis[67], and alcohol-related liver disease[73]. Xu et al[67] and Qi et al[68] suggest that serum miR-122 is a potential marker for the discrimination of HCC patients from healthy controls, but not HCC patients from patients with chronic hepatitis. Therefore, these authors proposed serum miR-122 as a novel biomarker for liver injury but not specifically for HCC. HCC is a highly complex, multifactorial and heterogeneous disease, and numerous miRNAs are dysregulated during HCC onset and progression. Therefore, a combination of multiple circulating miRNAs or a plasma/serum miRNA panel instead of a single circulating miRNA may offer more specificity and sensitivity as biomarkers for HCC diagnosis and prognosis prediction.

Plasma/serum miRNA panel as biomarkers for HCC diagnosis

Jiang et al[74] demonstrated that three serum miRNAs (miR-10b, miR-106b, and miR-181a) discriminated HCC patients from normal controls (AUC of 0.85, 0.82, and 0.89, respectively). However, the ability of single serum miRNA to differentiate CLD patients from normal controls was not satisfactory. This report indicated that the panel of three serum miRNAs displayed better performance compared to a single serum miRNA assay, with an AUC of 0.94 in discriminating HCC patients from normal controls and 0.91 in discriminating HCC patients from CLD.

Tan et al[12] preformed a study of 667 subjects (261 HCC patients, 233 cirrhosis patients, and 173 healthy controls) to identify a serum miRNA panel for use as biomarkers in the diagnosis of HBV-related HCC. Tan et al[12] first used sequencing to analyze miRNAs that were differently expressed in serum samples obtained from three patients with HBV-related HCC compared to sera from three cirrhosis patients, and three healthy controls. Secondly, differently expressed miRNAs were validated using qRT-PCR in 20 HBV-related HCC patients, 20 cirrhosis patients and 20 healthy controls in the biomarker selection stage. Subsequently, 135 HBV-related HCC patients, 132 cirrhosis patients and 90 healthy controls formed a training set. Finally, the established serum miRNA panel was tested in an independent cohort in the validation phase (103 HBV-related HCC patients, 78 cirrhosis patients, and 60 healthy controls). These data identified eight miRNAs (miR-206, miR-141-3p, miR-433-3p, miR-1228-5p, miR-199a-5p, miR-122-5p, miR-192-5p, and miR-26a-5p) and established a serum miRNA panel that provided high diagnostic accuracy for HCC (AUC = 0.887 and 0.879 for training and validation sets, respectively). These results demonstrated that a serum miRNA panel could differentiate HBV-related HCC from healthy controls (AUC = 0.893) and cirrhosis (AUC = 0.892) with a high degree of accuracy.

Similarly, Zhou et al[75] also attempted to identify a plasma miRNA panel for the diagnosis of HBV-related HCC. This study investigated 934 participants (healthy, chronic hepatitis B, cirrhosis, and HBV-related HCC). First, Zhou et al[75] used microarrays to screen 723 miRNAs in 137 plasma samples for the diagnosis of HCC in the discovery stage. Fifteen candidate miRNAs that were discovered via microarray were selected for further testing using qRT-PCR from 102 participants in the training stage. Seven miRNAs that were differentially expressed between the HCC and control groups (healthy, chronic hepatitis B, and cirrhosis) were further tested in an additional 305 participants. Finally, seven miRNAs were used to predict the probability of HCC diagnosis in an independent cohort of 390 patients in the validation phase. The results demonstrated that the plasma miRNA panel (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801) provided a high diagnostic accuracy of HCC (AUC = 0.864 and 0.888 for training and validation data set, respectively), and it differentiated HCC from healthy controls (AUC = 0.941), chronic hepatitis B (AUC = 0.842), and cirrhosis (AUC = 0.884), respectively.

Combination of serum/plasma miRNAs with AFP for HCC diagnosis

AFP is the most widely used and broadly known biomarker for HCC diagnosis, and the combination of AFP measurement and ultrasound at 6-mo intervals are the standard tools for the diagnosis and monitoring of HCC in China. However, the sensitivity and specificity of serum AFP levels are relatively unsatisfactory, especially for AFP-negative HCC and small-size HCC (< 3 cm). The testing of AFP levels was dropped from current surveillance guidelines in Europe and the United States because of its low sensitivity and specificity[12,76,77]. AFP is not an ideal biomarker for HCC, but some reports demonstrated that a combination of serum/plasma miRNAs with alkaline phosphatase (ALP) may be beneficial in HCC patients and improve the sensitivity and specificity of liver cancer diagnosis.

For example, Tomimaru et al[69] measured plasma miR-21 level using qRT-PCR in 126 HCC patients, 30 chronic hepatitis patients, and 50 healthy volunteers. Their results suggested that miR-21 levels were higher in HCC patients than in chronic hepatitis patients (AUC of 77.3; sensitivity of 61.1% and specificity of 83.3%) and healthy volunteers (AUC of 95.3; sensitivity of 87.3% and specificity of 96%). Notably, the combination of plasma miR-21 with AFP improved the differentiation power between HCC patients and patients with chronic hepatitis (AUC of 0.823; sensitivity of 81.0% and specificity of 80.0%) and healthy volunteers (AUC to 0.971; sensitivity of 92.9% and specificity of 94.0%). Qu et al[78] analyzed serum levels of three miRNAs, namely miR-16, miR-195, and miR-199a, either alone or in combination with conventional serum markers (AFP, ALP-L3 and DCP) to differentiate HCC from CLDs. These authors suggested that miR-16 was a more sensitive biomarker for HCC, and the combination of miR-16, AFP, AFP-L3, and DCP identified 92.4% of HCC cases with a high specificity (78.5%). These results demonstrated that the combination of serum/plasma miRNAs with already established markers (such as AFP) may improve the performance of HCC diagnosis.

Circulating miRNAs as prognostic biomarkers for HCC

Circulating miRNAs may also aid the prediction of HCC prognosis. For example, Xu et al[4] analyzed the prognostic role of serum miR-122 levels in 122 HCC patients, and their results revealed a higher overall survival rate in HCC patients with high serum miR-122 levels compared to low miR-122 levels. They also found that high serum miR-122 levels were independently associated with higher overall survival rates in HCC patients. These outcomes suggest that a high serum miR-122 level is a good biomarker of prognosis in HCC patients. Köberle et al[79] also found that HCC patients with higher miR-122 serum levels exhibited longer overall survival than individuals with lower miR-122 serum concentrations, but the serum miR-122 level was not independently associated with overall survival. However, Köberle et al[79] suggested that miR-1 serum levels were independently associated with overall survival, but miR-1 serum levels exhibited no relevant correlation with clinical chemistry liver parameters. Their data indicated that serum miR-1 might improve the predictive value of classical HCC staging scores. Li et al[80] found that high levels of miR-221 expression correlated with tumor size, cirrhosis and tumor stage in HCC patients. Their results also suggested that the overall survival rate of the high miR-221 expression group was significantly lower than that of the low miR-221 expression group. Therefore, serum miR-221 also might provide predictive significance for the prognosis of HCC patients.

Collectively, these data illustrate that circulating miRNAs may be used as non-invasive biomarkers for the diagnosis and prognosis of HCC, and these nucleotides may become promising next-generation biomarkers for HCC detection. The data described above are summarized in Table 1.

Table 1 Circulating microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma.

MicroRNAs	Diagnosis/prognosis	Up/downregulated in plasma/serum	Plasma/serum	Relevance	Ref.
miR-12	Yes/No	Upregulated	Serum	Compared with healthy control	[67]
miR-122	Yes/No	Upregulated	Serum		[67]
miR-223	Yes/No	Upregulated	Serum		[67]
miR-122	Yes/No	Upregulated	Serum	Compared with healthy control	[68]
miR-21	Yes/No	Upregulated	Plasma	Compared with chronic hepatitis or healthy control	[69]
miR-143	Yes/No	Upregulated	Serum	Compared with healthy control	[6]
miR-215	Yes/No	Upregulated	Serum		[6]
miR-10b	Yes/No	Upregulated	Serum	Compared with CLD or healthy control	[74]
miR-106b	Yes/No	Upregulated	Serum		[74]
miR-181a	Yes/No	Downregulated	Serum		[74]
miR-206	Yes/No	Upregulated	Serum	HBV-related HCC compared with cirrhosis or healthy control	[12]
miR-141-3p	Yes/No	Upregulated	Serum		[12]
miR-433-3p	Yes/No	Upregulated	Serum		[12]
miR-1228-5p	Yes/No	Upregulated	Serum		[12]
miR-199a-5p	Yes/No	Downregulated	Serum		[12]
miR-122-5p	Yes/No	Downregulated	Serum		[12]
miR-192-5p	Yes/No	Downregulated	Serum		[12]
miR-26a-5p	Yes/No	Downregulated	Serum		[12]
miR-122	Yes/No	Downregulated	Plasma	HBV-related HCC compared with chronic hepatitis B or healthy control	[75]
miR-192	Yes/No	Upregulated	Plasma		[75]
miR-21	Yes/No	Upregulated	Plasma		[75]
miR-223	Yes/No	Downregulated	Plasma		[75]
miR-26a	Yes/No	Downregulated	Plasma		[75]
miR-27a	Yes/No	Downregulated	Plasma		[75]
miR-801	Yes/No	Upregulated	Plasma		[75]
miR-16	Yes/No	Downregulated	Serum	Compared with CLD or healthy control	[78]
miR-21	Yes/No	Upregulated	Plasma	Compared with chronic hepatitis or healthy volunteers	[69]
miR-375d	Yes/No	Downregulated	Serum	Compared with healthy control	[87]
miR-199a-3p	Yes/No	Downregulated			[87]
miR-30c-5p	Yes/No	Upregulated	Serum	HCV-related HCC compared with healthy control	[15]
miR-223-3p	Yes/No	Downregulated	Serum		[15]
miR-302c-3p	Yes/No	Upregulated	Serum		[15]
miR-17-5p	Yes/No	Upregulated	Serum		[15]
miR-122	No/Yes	Upregulated	Serum	Improved overall survival	[4]
miR-1	No/Yes	Upregulated	Serum	Improved overall survival	[79]
miR-221	No/Yes	Upregulated	Serum	High serum miR-221 levels decreased survival rate	[81]

miRNAs: MicroRNAs; CLD: Chronic liver disease; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

CONCLUSION

The use of circulating miRNAs as biomarkers for HCC has received attention since the first circulating miRNAs signatures were reported as potential diagnostic tools in oncology in 2008. This review highlights the process of miRNAs biogenesis and elaborates the origins and types of circulating miRNAs. Notably, we have summarized recent advances in circulating miRNAs signatures as non-invasive biomarkers in the diagnosis and prognosis of HCC. Overall, our review illustrates the potential application of circulating miRNAs, either as a single marker or as a panel of circulating miRNAs or in combination with conventional markers, as biomarkers for HCC diagnosis and prognosis predictions.

Encouraging progress in the use of circulating miRNAs in HCC diagnosis and prognosis has been made, and circulating miRNAs are extremely promising biomarkers. However, there are no clinically used miRNAs biomarkers for HCC, and further investigation is required to overcome some of the challenges in their application. First, the origin of circulating miRNAs has not been fully elucidated. Circulating miRNAs in serum/plasma have a heterogeneous origin, including from blood cells, endothelia cells, and other high blood-flow organs, which demonstrates that the expression of tumor-specific miRNA signatures may be masked by circulating miRNAs from other origins[19,81-83]. Another issue is that well-standardized protocols are not implemented for pre-analytical decisions of circulating miRNAs (e.g., sample storage, sample processing, the profiling method) to post-analytical processing (e.g., data normalization), which makes definitive comparisons between studies difficult[43,84]. Unfortunately, there is no widely accepted endogenous normalization control for circulating miRNAs, despite the use of qRT-PCR, which is the most commonly used technology for the detection of miRNAs in circulation. Furthermore, most miRNAs studies use small sample sizes, limited number of screened miRNAs, fail to differentiate HCC from hepatitis B and C, and lack large-scale prospective studies[9,20,74]. Moreover, much work is also required to compare values of circulating protein-bound miRNAs and microparticle miRNAs in different HCC patients. Finally, it is very important to use appropriate controls that are well matched in age, race, gender, etiology and severity of underlying liver disease when evaluating the sensitivity and specificity of circulating miRNAs for the diagnosis and monitoring of HCC[20,85,86].

Research on circulating miRNAs is in its infancy, and there are some challenges in the clinical application of circulating miRNAs. However, an improved understanding of the origins, stability, detection methods, and roles of circulating miRNAs in HCC will support the great potential of circulating miRNAs to become diagnostic and prognostic tools for HCC in the future.